DNAH12
Dynein axonemal heavy chain 12
Also known as: DHC3, DLP12, DNAH12L, DNAH7L, Dnahc3, DNHD2, DYH12_HUMAN, FLJ40427, FLJ44290, hdhc3, HL-19
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6ZR08
- Gene
- DNAH12
- Ensembl
- ENSG00000174844
- Chromosome
- 3
- Canonical length
- 3092 aa
- Protein class
- Cancer-related genes, Predicted intracellular proteins
- Subcellular location
- Centrosome,Cytosol,Mid piece,Principal piece
OverviewNCBI Gene
Predicted to enable several functions, including ATP binding activity; ATP hydrolysis activity; and dynein intermediate chain binding activity. Predicted to be involved in microtubule-based movement. Predicted to be located in axoneme and microtubule. Predicted to be part of axonemal dynein complex. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
3092 residues, UniProt reviewed canonical sequence.
>Q6ZR08|DNAH12
1 MSDANKAAIA AEKEALNLKL PPIVHLPENI GVDTPTQSKL LKYRRSKEQQ QKINQLVIDG
61 AKRNLDRTLG KRTPLLPPPD YPQTMTSEMK KKGFNYIYMK QCVESSPLVP IQQEWLDHML
121 RLIPESLKEG KEREELLESL INEVSSDFEN SMKRYLVQSV LVKPPVKSLE DEGGPLPESP
181 VGLDYSNPWH SSYVQARNQI FSNLHIIHPT MKMLLDLGYT TFADTVLLDF TGIRAKGPID
241 CESLKTDLSI QTRNAEEKIM NTWYPKVINL FTKKEALEGV KPEKLDAFYS CVSTLMSNQL
301 KDLLRRTVEG FVKLFDPKDQ QRLPIFKIEL TFDDDKMEFY PTFQDLEDNV LSLVERIAEA
361 LQNVQTIPSW LSGTSTPVNL DTELPEHVLH WAVDTLKAAV HRNLEGARKH YETYVEKYNW
421 LLDGTAVENI ETFQTEDHTF DEYTEFIEKF LSLASEIMLL PQWIHYTMVR LDCEDLKTGL
481 TNKAKAFANI LLNDIASKYR KENECICSEF EAIKEHALKV PETTEEMMDL ISYVEKARTV
541 GIEELILRIQ ESKRQMSYFL DVFLFPQEDL ALNATVLMWP RKINPIFDEN DELIENAKHK
601 KENELMAKRE KLILEIEKES RRMEEFTEFA ELERMQQYVT DVRQLQKRIQ ESEEAVQFIN
661 KEEELFKWEL TKYPELDKLK VNIEPYQKFF NFVLKWQRSE KRWMDGGFLD LNGESMEADV
721 EEFSREIFKT LKFFQTKLKK ELQEKRKAAR KRSLEEEKIE EEPKDNATIT MCRMRARHWK
781 QISEIVGYDL TPDSGTTLRK VLKLNLTPYL EQFEVISAGA SKEFSLEKAM NTMIGTWEDI
841 AFHISLYRDT GVCILSSVDE IQAILDDQII KTQTMRGSPF IKPFEHEIKA WEDRLIRIQE
901 TIDEWLKVQA QWLYLEPIFC SEDIMQQMPE EGRQFQTVDR HWRDIMKFCA KDPKVLAATS
961 LTGLLEKLQN CNELLEKIMK GLNAYLEKKR LFFPRFFFLS NDEMLEILSE TKDPLRVQPH
1021 LKKCFEGIAK LEFLPNLDIK AMYSSEGERV ELIALISTSA ARGAVEKWLI QVEDLMLRSV
1081 HDVIAAARLA YPESARRDWV REWPGQVVLC ISQMFWTSET QEVISGGTEG LKKYYKELQN
1141 QLNEIVELVR GKLSKQTRTT LGALVTIDVH ARDVVMDMIK MGVSHDTDFL WLAQLRYYWE
1201 NENARVRIIN CNVKYAYEYL GNSPRLVITP LTDRCYRTLI GAFYLNLGGA PEGPAGTGKT
1261 ETTKDLAKAL AVQCVVFNCS DGLDYLAMGK FFKGLASSGA WACFDEFNRI ELEVLSVVAQ
1321 QILCIQRAIQ QKLVVFVFEG TELKLNPNCF VAITMNPGYA GRSELPDNLK VLFRTVAMMV
1381 PNYALIAEIS LYSYGFLNAR PLSVKIVMTY RLCSEQLSSQ FHYDYGMRAV KAVLVAAGNL
1441 KLKYPNENED ILLLRSIKDV NEPKFLSHDI PLFNGITSDL FPGIKLPEAD YHEFLECAHE
1501 ACNVHNLQPV KFFLEKIIQT YEMMIVRHGF MLVGEPFAAK TKVLHVLADT LTLMNEHGYG
1561 EEEKVIYRTV NPKSITMGQL FGQFDPVSHE WTDGIVANTF REFALSETPD RKWVVFDGPI
1621 DTLWIESMNT VLDDNKKLCL MSGEIIQMSP QMSLIFETMD LSQASPATVS RCGMIYLEPS
1681 QLGWEPLVSS WLNSLKGPLC EPEYQALLRG LFAWLIPPSL NQRVELFQLN YLYTTIVSKI
1741 LKILITFRIS NYFKYVPLKT QCTFIKFFLH QQACFIFSLI WSIGGSCDTD GRRVFDTFIR
1801 LIILGKDDEN PVPDSVGKWE CPFDEKGLVY DYMYELKNKG RWVHWNELIK NTNLGDKQIK
1861 IQDIIVPTMD TIRYTFLMDL SITYAKPLLF VGPTGTGKSV YVKDKLMNHL EKDQYFPFYI
1921 NLSARTSANQ VQNIIMARLD KRRKGVFGPP MGKKCIIFID DMNMPALEKY GAQPPIELLR
1981 QFFDCGHWYD LKDTSKITLV DIELIAAMGP PGGGRNPVTP RCIRHFNICS INSFSDETMV
2041 RIFSSIVAFY LRTHEFPPEY FVIGNQIVNG TMEIYKQSVE NLLPTPTKSH YTFNLRDFSR
2101 VIRGCLLIER DAVANKHTMI RLFVHEVLRV FYDRLINDDD RRWLFQLTKT VIKDHFKESF
2161 HSIFSHLRKQ NAPVTEEDLR NLMFGDYMNP DLEGDDRVYI EIPNIHHFSD VVDQCLDEYN
2221 QTHKTRMNLV IFRYVLEHLS RICRVLKQSG GNALLVGLGG SGRQSLTRLA TSMAKMHIFQ
2281 PEISKSYGMN EWREDMKSFI AVPVTNRIVD NKSKILEKRL RYLNDHFTYN LYCNICRSLF
2341 EKDKLLFSFL LCANLLLARK EIEYQELMFL LTGGVSLKSA EKNPDPTWLQ DKSWEEICRA
2401 SEFPAFRGLR QHFCEHIYEW REIYDSKEPH NAKFPAPMDK NLNELQKIII LRCLRPDKIT
2461 PAITNYVTDK LGKKFVEPPP FDLTKSYLDS NCTIPLIFVL SPGADPMASL LKFANDKSMS
2521 GNKFQAISLG QGQGPIAAKM IKAAIEEGTW VCLQNCHLAV SWMPMLEKIC EDFTSETCNS
2581 SFRLWLTSYP SSKFPVTILQ NGVKMTNEPP TGLRLNLLQS YLTDPVSDPE FFKGCRGKEL
2641 AWEKLLFGVC FFHALVQERK KFGPLGWNIP YGFNESDLRI SIRQLQLFIN EYDTIPFEAI
2701 SYLTGECNYG GRVTDDWDRR LLLTMLADFY NLYIVENPHY KFSPSGNYFA PPKGTYEDYI
2761 EFIKKLPFTQ HPEIFGLHEN VDISKDLQQT KTLFESLLLT QGGSKQTGAS GSTDQILLEI
2821 TKDILNKLPS DFDIEMALRK YPVRYEESMN TVLVQEMERF NNLIITIRNT LRDLEKAIKG
2881 VVVMDSALEA LSGSLLVGKV PEIWAKRSYP SLKPLGSYIT DFLARLNFLQ DWYNSGKPCV
2941 FWLSGFFFTQ AFLTGAMQNY ARKYTTPIDL LGYEFEVIPS DTSDTSPEDG VYIHGLYLDG
3001 ARWDRESGLL AEQYPKLLFD LMPIIWIKPT QKSRIIKSDA YVCPLYKTSE RKGTLSTTGH
3061 STNFVIAMLL KTDQPTRHWI KRGVALLCQL DDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DNAH12 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0
- Highest tissue expression
- 9.7 nTPM
Expression across tissuesHPA
Tissue
- fallopian tube: 9.7 nTPM
- choroid plexus: 8.7 nTPM
- testis: 8.4 nTPM
- lung: 3.5 nTPM
- hippocampal formation: 1.6 nTPM
- hypothalamus: 1.6 nTPM
Single-cell type
- respiratory ciliated cells: 2,669 nCPM
- ependymal cells: 1,304 nCPM
- endometrial ciliated cells: 1,090 nCPM
- fallopian tube ciliated cells: 851 nCPM
- choroid plexus epithelial cells: 457 nCPM
- epididymal efferent duct ciliated cells: 351 nCPM
Immune cell
- NK-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- choroid plexus: 14 nTPM
- midbrain: 10 nTPM
- medulla oblongata: 9.4 nTPM
- spinal cord: 5.3 nTPM
- pons: 3.7 nTPM
- white matter: 2.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about DNAH12.
Disease | AllUniProt
Conditions DNAH12 is implicated in, by any mechanism.
- Spermatogenic failure 100 (SPGF100) MIM:621209
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 384 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Spermatogenic failure 100
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.12
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.62
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- ATP binding
- dynein intermediate chain binding
- dynein light intermediate chain binding
- minus-end-directed microtubule motor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- AAA+ ATPase domain
- Dynein heavy chain, D6 P-loop domain
- Dynein heavy chain, linker
- Dynein heavy chain, AAA module D4
- Dynein heavy chain
- P-loop containing nucleoside triphosphate hydrolase
- Dynein heavy chain, hydrolytic ATP-binding dynein motor region
- Dynein heavy chain, C-terminal domain
- Dynein heavy chain, AAA 5 extension domain
- Dynein heavy chain 3, AAA+ lid domain
- Dynein heavy chain, AAA lid domain
- Dynein heavy chain, AAA lid domain superfamily
- Dynein heavy chain, domain 2, N-terminal
- Dynein heavy chain, linker, subdomain 3
- Dynein heavy chain, AAA1 domain, small subdomain
- Dynein heavy chain, C-terminal domain, barrel region
- Dynein heavy chain region D6 P-loop domain
- Dynein heavy chain, N-terminal region 2
- Hydrolytic ATP binding site of dynein motor region
- P-loop containing dynein motor region
- P-loop containing dynein motor region D4
- Dynein heavy chain AAA lid domain
- AAA+ lid domain
- Dynein heavy chain AAA lid domain
- Dynein heavy chain C-terminal domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of DNAH12 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DNAH12 as an antibody target. Whether an autoantibody or antibody against DNAH12 could matter depends on whether native DNAH12 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DNAH12 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label DNAH12 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...